Anagrelide: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Anagrelide. Educational only — not medical advice.
Reported adverse reactions
| Reaction | Highest frequency reported* |
|---|---|
| Headache…………………………………… | 43.5% |
| Palpitations………………………………… | 26.1% |
| Diarrhea……………………………………… | 25.7% |
| Asthenia……………………………………… | 23.1% |
| Edema, other………………………………… | 20.6% |
| Nausea……………………………………… | 17.1% |
| Abdominal pain……………………………… | 16.4% |
| Dizziness…………………………………… | 15.4% |
| Pain, other…………………………………… | 15% |
| Dyspnea……………………………………… | 11.9% |
| Flatulence…………………………………… | 10.2% |
| Vomiting…………………………………… | 9.7% |
| Fever………………………………………… | 8.9% |
| Peripheral edema…………………………… | 8.5% |
| Rash, including urticaria…………………… | 8.3% |
| Chest pain…………………………………… | 7.8% |
| Anorexia…………………………………… | 7.7% |
| Tachycardia………………………………… | 7.5% |
| Pharyngitis…………………………………… | 6.8% |
| Malaise……………………………………… | 6.4% |
*Highest percentage across placebo-controlled trial tables summarized in current labeling.
Labeled uses
Anagrelide hydrochloride capsules are indicated for the treatment of patients with thrombocythemia, secondary to myeloproliferative disorders, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events (see CLINICAL STUDIES , DOSAGE AND ADMINISTRATION ).
Source: FDA labeling via NIH DailyMed (set 5e6cf1e5…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.